1-year ‘satisfactory’ application of insurance benefit for Daklinza for treatment of hepatitis C

Published: 2017-03-15 13:54:05

Updated: 2017-03-15 13:54:05

After the mass hepatitis C infection incident, the Korea Centers for Disease Control and Prevention(KCDC) recently revealed the reaction of Korean hepatitis C patients to interferon and the effect of treatment after adopting DAAs(direct-acting antivirals) in the ‘Status and Measure for Hepatitis C in Korea’ research report.

The report calculated the rate of interferon-based treatment will be l...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.